These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 24722171)

  • 41. Testosterone therapy and risk of myocardial infarction: a pharmacoepidemiologic study.
    Etminan M; Skeldon SC; Goldenberg SL; Carleton B; Brophy JM
    Pharmacotherapy; 2015 Jan; 35(1):72-8. PubMed ID: 25582846
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
    Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Testosterone Therapy Did Not Increase Major Cardiovascular Events.
    Harris E
    JAMA; 2023 Jul; 330(3):211. PubMed ID: 37379018
    [No Abstract]   [Full Text] [Related]  

  • 44. Non-HDL cholesterol as a therapeutic goal.
    Brea A; Hernández-Mijares A; Millán J; Ascaso JF; Blasco M; Díaz A; Mantilla T; Pedro-Botet JC; Pintó X
    Clin Investig Arterioscler; 2019 Dec; 31 Suppl 2():28-33. PubMed ID: 31806265
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Testosterone replacement therapy and cardiovascular risk.
    Gagliano-Jucá T; Basaria S
    Nat Rev Cardiol; 2019 Sep; 16(9):555-574. PubMed ID: 31123340
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mendelian randomization suggests non-causal associations of testosterone with cardiometabolic risk factors and mortality.
    Haring R; Teumer A; Völker U; Dörr M; Nauck M; Biffar R; Völzke H; Baumeister SE; Wallaschofski H
    Andrology; 2013 Jan; 1(1):17-23. PubMed ID: 23258625
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis.
    Kohn TP; Mata DA; Ramasamy R; Lipshultz LI
    Eur Urol; 2016 Jun; 69(6):1083-90. PubMed ID: 26874809
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety of testosterone replacement therapy.
    Med Lett Drugs Ther; 2016 Mar; 58(1490):33-4. PubMed ID: 26963153
    [No Abstract]   [Full Text] [Related]  

  • 49. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Androgen activity, ischaemic heart disease and risk factors among men in NHANES III.
    Schooling CM
    Eur J Clin Invest; 2013 Dec; 43(12):1273-81. PubMed ID: 24117250
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Testosterone administration in older men.
    Matsumoto AM
    Endocrinol Metab Clin North Am; 2013 Jun; 42(2):271-86. PubMed ID: 23702401
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Testosterone therapy and cardiovascular risk: advances and controversies.
    Morgentaler A; Miner MM; Caliber M; Guay AT; Khera M; Traish AM
    Mayo Clin Proc; 2015 Feb; 90(2):224-51. PubMed ID: 25636998
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Endogenous androgen exposures and ischemic heart disease, a separate sample Mendelian randomization study.
    Zhao JV; Schooling CM
    Int J Cardiol; 2016 Nov; 222():940-945. PubMed ID: 27526363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
    Ridker PM; Genest J; Boekholdt SM; Libby P; Gotto AM; Nordestgaard BG; Mora S; MacFadyen JG; Glynn RJ; Kastelein JJ;
    Lancet; 2010 Jul; 376(9738):333-9. PubMed ID: 20655105
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Testosterone for women: necessary or noxious?
    Katz A
    AWHONN Lifelines; 2006; 10(3):208-9. PubMed ID: 16792707
    [No Abstract]   [Full Text] [Related]  

  • 56. Management of Hypogonadism in Cardiovascular Patients: What Are the Implications of Testosterone Therapy on Cardiovascular Morbidity?
    Tanna MS; Schwartzbard A; Berger JS; Underberg J; Gianos E; Weintraub HS
    Urol Clin North Am; 2016 May; 43(2):247-60. PubMed ID: 27132583
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of testosterone in chronic kidney disease and kidney function in men and women: a bi-directional Mendelian randomization study in the UK Biobank.
    Zhao JV; Schooling CM
    BMC Med; 2020 Jun; 18(1):122. PubMed ID: 32493397
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Controversies in testosterone replacement therapy: testosterone and cardiovascular disease.
    Hwang K; Miner M
    Asian J Androl; 2015; 17(2):187-91. PubMed ID: 25652628
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease?
    Saad F
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():52-9. PubMed ID: 23280867
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Testosterone deficiency and cardiovascular mortality.
    Morgentaler A
    Asian J Androl; 2015; 17(1):26-31. PubMed ID: 25432501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.